Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CureVac (CVAC) Non-Current Deferred Tax Liability (2019 - 2025)

Historic Non-Current Deferred Tax Liability for CureVac (CVAC) over the last 6 years, with Q3 2025 value amounting to $265375.5.

  • CureVac's Non-Current Deferred Tax Liability changed N/A to $265375.5 in Q3 2025 from the same period last year, while for Sep 2025 it was $265375.5, marking a year-over-year change of. This contributed to the annual value of $242571.1 for FY2024, which is 9657.53% down from last year.
  • As of Q3 2025, CureVac's Non-Current Deferred Tax Liability stood at $265375.5.
  • CureVac's 5-year Non-Current Deferred Tax Liability high stood at $7.1 million for Q4 2023, and its period low was $57133.8 during Q4 2022.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $242571.1 (2024), whereas its average is $1.2 million.
  • Per our database at Business Quant, CureVac's Non-Current Deferred Tax Liability skyrocketed by 1229705.15% in 2023 and then crashed by 9657.53% in 2024.
  • Quarter analysis of 5 years shows CureVac's Non-Current Deferred Tax Liability stood at $212778.6 in 2021, then crashed by 73.15% to $57133.8 in 2022, then surged by 12297.05% to $7.1 million in 2023, then tumbled by 96.58% to $242571.1 in 2024, then increased by 9.4% to $265375.5 in 2025.
  • Its last three reported values are $265375.5 in Q3 2025, $256954.8 for Q2 2025, and $238777.8 during Q1 2025.